Berberine enhances the anti‑tumor activity of tamoxifen in drug‑sensitive MCF‑7 and drug‑resistant MCF‑7/TAM cells

Wen,Chunjie; Wu,Lanxiang; Fu,Lijuan; Zhang,Xue; Zhou,Honghao

doi:10.3892/mmr.2016.5490

Berberine enhances the anti‑tumor activity of tamoxifen in drug‑sensitive MCF‑7 and drug‑resistant MCF‑7/TAM cells

Authors:
- Chunjie Wen
- Lanxiang Wu
- Lijuan Fu
- Xue Zhang
- Honghao Zhou
View Affiliations

Affiliations: Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: July 8, 2016 https://doi.org/10.3892/mmr.2016.5490
Pages: 2250-2256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine, an isoquinoline alkaloid, has been previously demonstrated to possess anti‑breast cancer properties. Tamoxifen is widely used in the prevention and treatment of estrogen receptor-positive breast cancer. Thus, the aim of the present study was to assess whether berberine enhanced the anticancer effect of tamoxifen, and the underlying mechanism involved in this combined effect in tamoxifen-sensitive (MCF-7) and tamoxifen-resistant (MCF-7/TAM) cells using MTS, flow cytometry and western blot assays. The results indicated that berberine demonstrated dose‑ and time‑dependent anti‑proliferative activity in MCF‑7 and MCF‑7/TAM cells. Furthermore, the combination of berberine and tamoxifen induced cell growth inhibition more effectively than tamoxifen alone. The present study also demonstrated that combinational treatment is more effective in inducing G1 phase arrest and activating apoptosis compared tamoxifen alone, which may be due to upregulation of P21 expression and downregulation of the B‑cell CLL/lymphoma 2(Bcl‑2)/Bcl‑2 associated X protein ratio. The results of the present study suggested that berberine may potentially be useful as an adjuvant agent in cancer chemotherapy to enhance the effect of tamoxifen, which will be useful for anti‑tumor therapy and further research.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:296–300. 2003. View Article : Google Scholar : PubMed/NCBI
3	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
4	Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 22:7316–7339. 2003. View Article : Google Scholar : PubMed/NCBI
5	Lewis JS and Jordan VC: Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 591:247–263. 2005. View Article : Google Scholar : PubMed/NCBI
6	Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M and Shen K: Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. 18:701–720. 2013. View Article : Google Scholar : PubMed/NCBI
7	Charalambous C, Pitta CA and Constantinou AI: Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer. 13:2382013. View Article : Google Scholar : PubMed/NCBI
8	Mittal A, Tabasum S and Singh RP: Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft. Phytomedicine. 21:340–347. 2014. View Article : Google Scholar
9	Zhao Q, Wang J, Zou MJ, Hu R, Zhao L, Qiang L, Rong JJ, You QD and Guo QL: Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. Toxicol Lett. 197:201–210. 2010. View Article : Google Scholar : PubMed/NCBI
10	Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M and D'Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 224:53–65. 2005. View Article : Google Scholar : PubMed/NCBI
11	Wen CJ, Wu LX, Fu LJ, Yu J, Zhang YW, Zhang X and Zhou HH: Genomic screening for targets regulated by berberine in breast cancer cells. Asian Pac J Cancer Prev. 14:6089–6094. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Liu Q, Liu Z, Li B, Sun Z, Zhou H, Zhang X, Gong Y and Shao C: Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells. Mutat Res. 734:20–29. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lu B, Hu M, Liu K and Peng J: Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction. Toxicol In Vitro. 24:1482–1490. 2010. View Article : Google Scholar : PubMed/NCBI
14	Lu B, Zhao J, Xu L, Xu Y, Wang X and Peng J: Identification of molecular target proteins in berberine-treated cervix adenocarcinoma HeLa cells by proteomic and bioinformatic analyses. Phytother Res. 26:646–656. 2012. View Article : Google Scholar : PubMed/NCBI
15	Youn MJ, So HS, Cho HJ, Kim Y, Lee JH, Sohn JS, Kim YK, Chung SY and Park R: Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull. 31:789–795. 2008. View Article : Google Scholar : PubMed/NCBI
16	Lin TH, Kuo HC, Chou FP and Lu FJ: Berberine enhances inhi-bition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer. 8:582008. View Article : Google Scholar
17	Fan LX, Liu CM, Gao AH, Zhou YB and Li J: Berberine combined with 2-deoxy-d-glucose synergistically enhances cancer cell proliferation inhibition via energy depletion and unfolded protein response disruption. Biochim Biophys Acta. 1830:5175–5183. 2013. View Article : Google Scholar : PubMed/NCBI
18	Patil JB, Kim J and Jayaprakasha GK: Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol. 645:70–78. 2010. View Article : Google Scholar : PubMed/NCBI
19	Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, et al: Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA. 105:288–293. 2008. View Article : Google Scholar :
20	Liu Z, Liu Q, Xu B, Wu J, Guo C, Zhu F, Yang Q, Gao G, Gong Y and Shao C: Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res. 662:75–83. 2009. View Article : Google Scholar : PubMed/NCBI
21	Larsen MS, Bjerre K, Giobbie-Hurder A, Lænkholm AV, Henriksen KL, Ejlertsen B, Lykkesfeldt AE and Rasmussen BB: Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncol. 51:781–789. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lv L, Zheng L, Dong D, Xu L, Yin L, Xu Y, Qi Y, Han X and Peng J: Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: A potential new drug for treatment of glioblastoma multiforme. Food Chem Toxicol. 59:657–669. 2013. View Article : Google Scholar : PubMed/NCBI
23	Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D and Caldas C: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index. Clin Cancer Res. 12:2468–2475. 2006. View Article : Google Scholar : PubMed/NCBI
24	Cardoso F, Paesmans M, Larsimont D, Durbecq V, Bernard-Marty C, Rouas G, Dolci S, Sotiriou C, Piccart MJ and Di Leo A: Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer. 5:364–369. 2004. View Article : Google Scholar : PubMed/NCBI
25	Xu C, Kong X, Wang H, Zhang N, Kong X, Ding X, Li X and Yang Q: MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells. Cell Physiol Biochem. 33:1557–1567. 2014. View Article : Google Scholar : PubMed/NCBI